The concept of erectile function preservation (penile rehabilitation) in the patient after brachytherapy for prostate cancer

Brachytherapy

Volumn 11, Issue 2, 2012, Pages 87-96

  Stember, Doron S ^a   Mulhall, John P ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; Erectile function; PDE5 inhibitor; Prostate cancer; Radiation; Rehabilitation

Indexed keywords

CYCLIC GMP; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTAGLANDIN E1; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANDROGEN DEPRIVATION THERAPY; APOPTOSIS; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ENZYME SYNTHESIS; ERECTILE DYSFUNCTION; FOLLOW UP; HUMAN; IN VITRO STUDY; LIBIDO; LOW DRUG DOSE; MALE GENITAL SYSTEM FUNCTION; MEAN ARTERIAL PRESSURE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; ORGAN PRESERVATION; PATHOPHYSIOLOGY; PENILE BLOOD FLOW; PENIS ERECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; REPRODUCTIVE PROCEDURES; REVIEW; SEXUAL BEHAVIOR; SEXUAL HEALTH; SEXUALITY; TISSUE PRESERVATION; TREATMENT DURATION;

BRACHYTHERAPY; ERECTILE DYSFUNCTION; HUMANS; MALE; PENILE ERECTION; PENIS; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE;

EID: 84857801097     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.01.002     Document Type: Review

References (64)

1. What are the key statistics about prostate cancer?: American Cancer Society Available at: Accessed June 13, 2010. http://www.cancer.org/docroot/CRI/content/CRI_2_4_1X_What_are_the_key_statistics_for_prostate_cancer_36.asp?sitearea=
2. Incrocci L., Slob A.K., Levendag P.C. Sexual (dys)function after radiotherapy for prostate cancer: A review. Int J Radiat Oncol Biol Phys 2002, 52:681-693.
3. Taira A.V., Merrick G.S., Galsbreath R.W., et al. Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009, 75:639-648.
4. Singer P.A., Tasch E.S., Stocking C., et al. Sex or survival: Trade-offs between quality and quantity of life. J Clin Oncol 1991, 9:328-334.
5. Hu J.C., Kwan L., Saigal C.S., et al. Regret in men treated for localized prostate cancer. J Urol 2003, 169:2279-2283.
6. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of prostate volume and neoadjuvant androgen-deprivation therapy on urinary function following prostate brachytherapy. Cancer J 2004, 10:181-189.
7. 125 prostate brachytherapy in the community setting: Ten-year experience. Brachytherapy 2010, 9:S29.
8. Traish A.M., Park K., Dhir V., et al. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999, 140:1861.
9. Teloken P.E., Ohebshalom M., Mohideen N., et al. Analysis of the impact of androgen deprivation therapy on sildenafil citrate response following radiation therapy for prostate cancer. J Urol 2007, 178:2521-2525.
10. Dean R.C., Lue T.F. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am 2005, 32:379-395.
11. Mulhall J.P., Slovick R., Hotaling J., et al. Erectile dysfunction after radical prostatectomy: Hemodynamic and their correlation with the recovery of erectile function. J Urol 2002, 167:1371-1375.
12. Rogers C.G., Trock B.P., Walsh P.C. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: Surgical technique and results. Urology 2004, 64:148-151.
13. User H.M., Hairston J.H., Zelner D.J., et al. Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction. J Urol 2003, 169:1175.
14. Leungwattanakij S., Bivalacqua T.J., Usta M.F., et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 2003, 24:239.
15. Fajardo L.F. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005, 44:13-22.
16. Mulhall J., Ahmed A., Parker M., et al. The hemodynamics of erectile dysfunction following external beam radiation for prostate cancer. J Sex Med 2005, 3:432-437.
17. Zelefsky M.J., Eid J.F. Elucidating the etiology of erectile dysfunction after definitive therapy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998, 40:129-133.
18. Merrick G.S., Butler W.M., Dorsey A.T., et al. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2000, 48:1069-1074.
19. Carrier S., Hricak H., Lee S., et al. Radiation-induced decrease in nitric oxide synthase-containing nerves in the rat penis. Radiology 1995, 195:95-99.
20. Nehra A., Hakim L.S., Mulhall J.P., et al. Radiation therapy for prostate cancer: Penile hemodynamic and structural alterations. J Urol 1997, 157:180.
21. Hall S.J., Basile G., Bertero E.B., et al. Extensive corporeal fibrosis after penile irradiation. J Urol 1995, 153:372-377.
22. Merrick G.S., Butler W.M., Wallner K.E., et al. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002, 4:1055-1062.
23. Mulhall J.P., Yonover P., Sethi A., et al. Radiation exposure to the corporeal bodies during 3-dimensional conformal radiation therapy for prostate cancer. J Urol 2002, 167:539-542.
24. Moreland R.B., Traish A., McMillin M.A., et al. PGE1 suppresses the induction of collagen synthesis by transforming growth factor-beta 1 in human corpus cavernosum smooth muscle. J Urol 1995, 153:826-834.
25. Mueller A., Donahue J.F., Akin-Olugbade Y.A., et al. The effect of hyperbaric oxygen therapy on erectile function recovery in a rat cavernous injury model. J Sex Med 2008, 5:562-570.
26. Tal A., Mueller A., Mulhall J.P. The correlation between intracavernosal pressure and cavernosal blood oxygenation. J Sex Med 2009, 6:2722-2777.
27. Zhang R., Wang Y., Zhang L., et al. Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats. Stroke 2002, 33:2675-2680.
28. Zhang R.L., Zhang Z., Zhang L., et al. Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 2006, 83:213-1219.
29. Dosoretz A.M., Chen M.H., Salenius S.A., et al. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy. Cancer 2010, 116:837-842.
30. Rosano G.M., Aversa A., Vitale C., et al. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005, 47:214-220.
31. Desouza C., Parulkar A., Lumpkin D., et al. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002, 25:1336-1339.
32. Mulhall J.P., Parker M., Waters B.W., et al. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int 2010, 105:37-41.
33. Schiff J.D., Bar-Chama N., Cessareti J., et al. Early use of a phosphodiesterase inhibitor after brachytherapy restores and preserves erectile function. BJU Int 2006, 98:1255-1258.
34. Mulhall J.P., Müller A., Donohue J.F., et al. The functional and structural consequences of cavernous nerve injury are ameliorated by sildenafil citrate. J Sex Med 2008, 5:1126-1136.
35. Kovanecz I., Rambhatla A., Ferrini M.G., et al. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction that occurs after cavernosal nerve resection. BJU Int 2008, 101:203-210.
36. De Young L.X., Domes T., Carson J., et al. Endothelial rehabilitation: The impact of chronic PDE5 inhibitors on erectile function and protein alterations in cavernous tissue of diabetic rats. Eur Urol 2008, 54:213-220.
37. Ferrini M.G., Davila H.H., Kovanecz I., et al. Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 2006, 68:429-435.
38. Lysiak J.J., Yang S.K., Klausner A.P., et al. Tadalafil increases Akt and extracellular signal-regulated kinase 1/2 activation, and prevents apoptotic cell death in the penis following denervation. J Urol 2008, 179:779-785.
39. Montorsi F., Guazzoni G., Strambi L.F., et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective, randomized trial. J Urol 1997, 158:1408-1410.
40. Mulhall J., Land S., Parker M., et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med 2005, 2:532-540.
41. Montorsi F., Brock G., Lee J., et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol 2008, 54:924-931.
42. Kaye K.W., Olson D.J., Payne J.T. Detailed preliminary analysis of iodine-125 implantation for localized prostate cancer using percutaneous approach. J Urol 1995, 153:1020-1025.
43. Martinez A., Gonzalez J., Stromberg J., et al. Conformal prostate brachytherapy: Initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995, 33:1019-1027.
44. Stone N.N., Ramin S.A., Wesson M.F., et al. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 1995, 153:1555-1560.
45. Chaikin D.C., Broderick G.A., Malloy T.R., et al. Erectile dysfunction following minimally invasive treatments for prostate cancer. Urology 1996, 48:100-104.
46. Stock R.G., Stone N.N., DeWyngaert J.K., et al. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Cancer 1996, 77:2386-2392.
47. Stock R.G., Stone N.N., Iannuzzi C. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996, 35:267-272.
48. Arterbery V.E., Frazier A., Dalmia P., et al. Quality of life after permanent prostate implant. Surg Oncol 1997, 13:461-464.
49. Koutrouvelis P.G. Three-dimensional stereotactic posterior ischiorectal space computerized tomography guided brachytherapy of prostate cancer: A preliminary report. J Urol 1998, 159:142-145.
50. Joly F., Brune D., Couette J.E., et al. Health-related quality of life and sequelae in patients treated with brachytherapy and external beam irradiation for localized prostate cancer. Ann Oncol 1998, 9:751-757.
51. Sharkey J., Chovnick S.D., Behar R.J., et al. Outpatient ultrasound-guided palladium-103 brachytherapy for localized adenocarcinoma of the prostate: A preliminary report of 434 patients. Urology 1998, 51:796-803.
52. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999, 17:517-522.
53. Kestin L.L., Martinez A.A., Stromberg J.S., et al. Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer. J Clin Oncol 2000, 18:2869-2880.
54. Sánchez-Ortiz R.F., Broderick G., Rovner E.S., et al. Erectile function and quality of life after interstitial radiation therapy for prostate cancer. Int J Impot Res 2000, 12(Suppl. 3):18-24.
55. Sharkey J., Chovnick S.D., Behar R.J., et al. Minimally invasive treatment for localized adenocarcinoma of the prostate: Review of 1048 patients treated with ultrasound-guided palladium-103 brachytherapy. J Endourol 2000, 14:343-350.
56. Zelefsky M.J., Hollister T., Raben A. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate cancer implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000, 47:1261-1266.
57. Stock R.G., Kao J., Stone N.N. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. J Urol 2001, 165:436-439.
58. Talcott J.A., Clark J.A., Stark P.C. Long term treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated. J Urol 2001, 166:494-499.
59. Merrick G.S., Butler W.M., Wallner K.E., et al. Erectile function after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 62:437-447.
60. Cesaretti J.A., Kao J., Stone N.N., et al. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: Analysis at > or =7 years of follow-up. BJU Int 2007, 100:362-367.
61. Stone N.N., Stock R.G. Long term urinary, sexual, and rectal morbidity in patients treated with I-125 prostate brachytherapy followed up for minimum of 5 years. Urology 2007, 69:338-342.
62. Schafer J.W., Welzel G., Trojan L., et al. Long-term health-related quality-of-life outcomes after permanent prostate brachytherapy. Onkologie 2008, 11:599-603.
63. Aaltomaa S.H., Kataja V.V., Lahtinen T., et al. Eight years experience of local prostate cancer treatment with permanent I125 seed brachytherapy-morbidity and outcome results. Radiother Oncol 2009, 91:213-216.
64. Crook J., Borg J., Evans A., et al. 10-Year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. Int J Radiat Oncol Biol Phys 2011, 80:1323-1329.